Drug Design, Development and Therapy
Dovepress open access to scientific and medical research
Corrigendum
Open Access Full Text Article
Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum] Mumoli L, Palleria C, Gasparini S, et al. Drug Des Devel Ther. 2015;9:5719–5725. On page 5722, in Table 1, the notes section is missing; it should read: Klein et al34 data presented as percent reduction in seizure frequency over placebo per 28 days. On page 5722, left column, line 8, the sentence “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 9.2% and 20.5% in the BRV 50 and 100 mg/d groups, respectively” should read “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 10.2%, 9.2% and 20.5% in the BRV 20, 50 and 100 mg/d groups, respectively”. On page 5722, right column, line 9, the sentence “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg” should read “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency over placebo was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg”.
On page 5723, left column, line 22, the sentence “Currently an open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of BRV is ongoing (BRITE study-NCT01339559)” should read “Currently four openlabel, multicenter, follow-up studies to evaluate the longterm safety and efficacy of BRV are ongoing: N01125 (NCT00175916), N01199 (NCT00150800), N01372 (NCT01728077), and N01379 - BRITE (NCT01339559)”. On page 5724, the first sentence of the Conclusion should read “BRV is a novel AED whose efficacy in partial epilepsies has been studied and established in six randomized controlled trials;30–35 furthermore, two recent meta-analyses have confirmed significant effects for BRV in patients with refractory partial seizures.29,43” In the reference list, page 5725, reference 34 (Klein et al), the link should be: http://www.abstracts2view.com/aan/ view.php?nu=AAN15L1_S31.009, which links directly to the abstract text.
Dovepress
Drug Design, Development and Therapy
Publish your work in this journal Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which
has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
6509
submit your manuscript | www.dovepress.com
Drug Design, Development and Therapy 2015:9 6509
Dovepress
© 2015 Mumoli et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://dx.doi.org/10.2147/DDDT.S101194
Dovepress open access to scientific and medical research
Corrigendum
Open Access Full Text Article
Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum] Mumoli L, Palleria C, Gasparini S, et al. Drug Des Devel Ther. 2015;9:5719–5725. On page 5722, in Table 1, the notes section is missing; it should read: Klein et al34 data presented as percent reduction in seizure frequency over placebo per 28 days. On page 5722, left column, line 8, the sentence “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 9.2% and 20.5% in the BRV 50 and 100 mg/d groups, respectively” should read “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 10.2%, 9.2% and 20.5% in the BRV 20, 50 and 100 mg/d groups, respectively”. On page 5722, right column, line 9, the sentence “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg” should read “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency over placebo was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg”.
On page 5723, left column, line 22, the sentence “Currently an open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of BRV is ongoing (BRITE study-NCT01339559)” should read “Currently four openlabel, multicenter, follow-up studies to evaluate the longterm safety and efficacy of BRV are ongoing: N01125 (NCT00175916), N01199 (NCT00150800), N01372 (NCT01728077), and N01379 - BRITE (NCT01339559)”. On page 5724, the first sentence of the Conclusion should read “BRV is a novel AED whose efficacy in partial epilepsies has been studied and established in six randomized controlled trials;30–35 furthermore, two recent meta-analyses have confirmed significant effects for BRV in patients with refractory partial seizures.29,43” In the reference list, page 5725, reference 34 (Klein et al), the link should be: http://www.abstracts2view.com/aan/ view.php?nu=AAN15L1_S31.009, which links directly to the abstract text.
Dovepress
Drug Design, Development and Therapy
Publish your work in this journal Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which
has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
6509
submit your manuscript | www.dovepress.com
Drug Design, Development and Therapy 2015:9 6509
Dovepress
© 2015 Mumoli et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://dx.doi.org/10.2147/DDDT.S101194
